{"entity":{"id":"nct06600022","kind":"trial","name":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","aka":[],"tldr":"A phase 1/2 trial of SCTB41 in advanced solid tumours, run by Sinocelltech Ltd., now recruiting.","summary":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. is a phase 1/2 interventional study registered as NCT06600022 by Sinocelltech Ltd., with 441 participants planned, started 2024-10-10 and due to reach its primary completion in 2027-04-30. Interventions recorded: SCTB41.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06600022","url":"https://clinicaltrials.gov/study/NCT06600022"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sctb41"],"companies":["sinocelltech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06600022","phase":"1/2","setting":"A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB41 in Patients with Advanced Malignant Solid Tumours","sponsor":"Sinocelltech Ltd.","enrolled":441,"outcomes":[]},"route":"/trials/nct06600022/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"sctb41","kind":"drug","name":"SCTB41","route":"/drugs/sctb41/"}],"company":[{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/"}]}}